Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation

被引:5
|
作者
Miguel Rivera-Caravaca, Jose [1 ]
Marin, Francisco [1 ]
Asuncion Esteve-Pastor, Maria [1 ]
Galvez, Josefa [2 ]
Lip, Gregory Y. H. [3 ,4 ,5 ]
Vicente, Vicente [2 ]
Roldan, Vanessa [2 ]
机构
[1] Univ Murcia, Hosp Clin Univ Virgen de la Arrixaca, Inst Murciano Invest Biosanitaria IMIB Arrixaca, Dept Cardiol,CIBERCV, Murcia, Spain
[2] Univ Murcia, Hosp Gen Univ Morales Meseguer, Inst Murciano Invest Biosanitaria IMIB Arrixaca, Dept Hematol & Clin Oncol, Murcia, Spain
[3] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England
[4] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[5] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
来源
BMJ OPEN | 2019年 / 9卷 / 12期
关键词
CLINICAL CLASSIFICATION SCHEMES; BLEEDING RISK-FACTORS; NATIONAL REGISTRY; PREDICTING STROKE; SCORE; ANTICOAGULATION; STRATIFICATION; HEMORRHAGE; WARFARIN; DEFINITION;
D O I
10.1136/bmjopen-2019-033712
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Atrial fibrillation (AF) is characterised by a high stroke risk. Vitamin K antagonists (VKAs) are the most commonly used oral anticoagulants (OACs) in Spain, but their efficacy and safety depend on the time in therapeutic range of International Normalized Ratio (INR) 2.0-3.0 over 65%-70%. Unfortunately, the difficulties of maintaining an optimal level of anticoagulation and the complications of VKAs (particularly haemorrhagic ones), frequently lead to cessation of this therapy, which has been associated with higher risk of adverse events (AEs), including ischaemic stroke. Our aims are as follows: (1) to evaluate the quality of oral anticoagulation with VKAs, the prevalence of poor quality of anticoagulation, and to identify factors predisposing to poor quality anticoagulation; and (2) to identify patients who will stop OAC and to investigate what factors influence the decision of OAC withdrawal. Methods and analysis Prospective observational cohort study including outpatients newly diagnosed with AF and naive for OACs from July 2016 to June 2018 in an anticoagulation clinic. Patients with prosthetic heart valves, rheumatic mitral valves or valvular AF will be excluded. Follow-up will extend for up to 3 years. During this period, the INR results and changes in the anticoagulant therapy will be recorded, as well as all AEs, or any other information that would be relevant to the proper conduct of research. Ethics and dissemination All patients were informed about the nature and purpose of the study, and the protocol was approved by the Ethics Committee of Hospital General Universitario Morales Meseguer (reference: EST:20/16). This is an observational study focusing on 'real life' practice and therefore all treatments and follow-up will be performed in accordance to the routine clinical practice with no specific interventions or visits. The results of our study will be disseminated by presentations at national and international meetings, and publications in peer-reviewed journals.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation The Loire Valley Atrial Fibrillation Project
    Banerjee, Amitava
    Fauchier, Laurent
    Bernard-Brunet, Anne
    Clementy, Nicolas
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (03) : 549 - 556
  • [22] Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation
    Hilkens, Nina A.
    Algra, Ale
    Greving, Jacoba P.
    STROKE, 2017, 48 (11) : 3142 - +
  • [23] Impact of gender: Rivaroxaban for patients with atrial fibrillation in theXANTUSreal-world prospective study
    Camm, A. John
    Amarenco, Pierre
    Haas, Sylvia
    Bach, Miriam
    Kirchhof, Paulus
    Kuhls, Silvia
    Lambelet, Marc
    Turpie, Alexander G. G.
    CLINICAL CARDIOLOGY, 2020, 43 (12) : 1405 - 1413
  • [24] Age threshold for anticoagulation in patients with atrial fibrillation: A Swedish nationwide observational study
    Andersson, Tommy
    Aspberg, Sara
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 326 : 92 - 97
  • [25] Prevalence, incidence and predictive factors of atrial fibrillation in geriatric patients-A prospective observational study
    Ebelt, Henning
    Goetze, Markus
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2024, 57 (02): : 120 - 125
  • [26] Anticoagulation in Very Old Patients with Atrial Fibrillation (AVOPA): A Descriptive Observational Study
    Hupfer, Maximilian
    Gosch, Markus
    DRUGS-REAL WORLD OUTCOMES, 2021, 8 (04) : 603 - 614
  • [27] Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study
    Bonde, Anders Nissen
    Blanche, Paul
    Staerk, Laila
    Gerds, Thomas Alexander
    Gundlund, Anna
    Gislason, Gunnar
    Torp-Pedersen, Christian
    Lip, Gregory Y. H.
    Hlatky, Mark A.
    Olesen, Jonas Bjerring
    EUROPEAN HEART JOURNAL, 2019, 40 (46) : 3782 - 3790
  • [28] Risk Factors for Stroke and Thromboembolism in Relation to Age Among Patients With Atrial Fibrillation The Loire Valley Atrial Fibrillation Project
    Olesen, Jonas Bjerring
    Fauchier, Laurent
    Lane, Deirdre A.
    Taillandier, Sophie
    Lip, Gregory Y. H.
    CHEST, 2012, 141 (01) : 147 - 153
  • [29] Effects of oral anticoagulant therapy in older medical in-patients with atrial fibrillation: a prospective cohort observational study
    Bo, Mario
    Li Puma, Federica
    Martini, Marco Badinella
    Falcone, Yolanda
    Iacovino, Marina
    Grisoglio, Enrica
    Menditto, Elena
    Fonte, Gianfranco
    Brunetti, Enrico
    Isaia, Giovanni Carlo
    D'Ascenzo, Fabrizio
    Gaita, Fiorenzo
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2017, 29 (03) : 491 - 497
  • [30] Anticoagulation Therapy for Atrial Fibrillation
    Hylek, Elaine M.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (02) : 147 - 152